GEN Exclusives

More »

GEN News Highlights

More »
Dec 15, 2009

Molecular Partners Raises Almost $45M to Support Phase II Trials in Ophthalmology

  • Germany-based Molecular Partners raised CHF 46 million (about $44.24 million) in a Series B equity investment round. The company aims to use the new funds to progress its lead VEGF antagonist, MP0112, into Phase II studies in two separate ophthalmology indications. The financing will also be used to support development of its preclinical pipeline of DARPin candidates.

    DARPins are a class of therapeutic proteins that combine the high specificity, selectivity, and safety of mAbs with advantages of small molecules, including high-stability and low-cost production, according to Molecular Partners.

    In May the company reported the early achievement of all milestones in the research phase of its collaboration with Centocor. The alliance is focused on developing DARPin antagonists against two undisclosed inflammatory disease targets. Molecular Partners also has ongoing DARPin collaborations with Roche and Bayer Schering Pharma.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »